1207113-81-2Relevant articles and documents
Design, synthesis and prostate cancer cell-based studies of analogs of the Rho/MKL1 transcriptional pathway inhibitor, CCG-1423
Evelyn, Chris R.,Bell, Jessica L.,Ryu, Jenny G.,Wade, Susan M.,Kocab, Andrew,Harzdorf, Nicole L.,Hollis Showalter,Neubig, Richard R.,Larsen, Scott D.
scheme or table, p. 665 - 672 (2010/06/21)
We recently identified bis(amide) CCG-1423 (1) as a novel inhibitor of RhoA/C-mediated gene transcription that is capable of inhibiting invasion of PC-3 prostate cancer cells in a Matrigel model of metastasis. An initial structure-activity relationship study focusing on bioisosteric replacement of the amides and conformational restriction identified two compounds, 4g and 8, with improved selectivity for inhibition of RhoA/C-mediated gene transcription and attenuated cytotoxicity relative to 1. Both compounds were also capable of inhibiting cell invasion with equal efficacy to 1 but with less attendant cytotoxicity.
